• +1-646-491-9876
    • +91-20-67278686

    Search

    Pulmonary Hypertension - Pipeline Review, H1 2015

    Pulmonary Hypertension - Pipeline Review, H1 2015

    • Report Code ID: RW0001172449
    • Category Pharmaceuticals
    • No. of Pages 226
    • Publication Month Jan-15
    • Publisher Name Global Markets Direct
    Pulmonary Hypertension-Pipeline Review, H1 2015

    Summary

    Publisher's, 'Pulmonary Hypertension-Pipeline Review, H1 2015', provides an overview of the Pulmonary Hypertension's therapeutic pipeline.

    This report provides comprehensive information on the therapeutic development for Pulmonary Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Hypertension and special features on late-stage and discontinued projects.

    Publisher's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publisher's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Publisher's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

    The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

    Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

    Scope

    - The report provides a snapshot of the global therapeutic landscape of Pulmonary Hypertension
    - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in the therapeutics development for Pulmonary Hypertension and enlists all their major and minor projects
    - The report summarizes all the dormant and discontinued pipeline projects
    - A review of the Pulmonary Hypertension products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - A detailed assessment of monotherapy and combination therapy pipeline projects
    - Coverage of the Pulmonary Hypertension pipeline on the basis of target, MoA, route of administration and molecule type
    - Latest news and deals relating related to pipeline products

    Reasons to buy

    - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Identify and understand important and diverse types of therapeutics under development for Pulmonary Hypertension
    - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
    - Devise corrective measures for pipeline projects by understanding Pulmonary Hypertension pipeline depth and focus of Indication therapeutics
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
    Table of Contents
    Table of Contents 2
    List of Tables 5
    List of Figures 7
    Introduction 8
    Global Markets Direct Report Coverage 8
    Pulmonary Hypertension Overview 9
    Therapeutics Development 10
    Pipeline Products for Pulmonary Hypertension-Overview 10
    Pipeline Products for Pulmonary Hypertension-Comparative Analysis 11
    Pulmonary Hypertension-Therapeutics under Development by Companies 12
    Pulmonary Hypertension-Therapeutics under Investigation by Universities/Institutes 17
    Pulmonary Hypertension-Pipeline Products Glance 18
    Late Stage Products 18
    Clinical Stage Products 19
    Early Stage Products 20
    Pulmonary Hypertension-Products under Development by Companies 21
    Pulmonary Hypertension-Products under Investigation by Universities/Institutes 26
    Pulmonary Hypertension-Companies Involved in Therapeutics Development 27
    Actelion Ltd 27
    APT Therapeutics, Inc. 28
    Arena Pharmaceuticals, Inc. 29
    Asahi Kasei Pharma Corp. 30
    Ascendis Pharma A/S 31
    Bayer AG 32
    Bial-Portela & Ca, S.A. 33
    Biolab Sanus Farmaceutica Ltda. 34
    Cardioxyl Pharmaceuticals, Inc. 35
    Carolus Therapeutics, Inc. 36
    Celladon Corporation 37
    Celsion Corporation 38
    Corridor Pharmaceuticals Inc. 39
    Cytokinetics, Inc. 40
    Eli Lilly and Company 41
    Gilead Sciences, Inc. 42
    HanAll Biopharma Co., Ltd. 43
    Hanmi Pharmaceuticals, Co. Ltd. 44
    Ikaria Inc. 45
    Insmed Incorporated 46
    Ironwood Pharmaceuticals, Inc. 47
    Lacer, S.A. 48
    Longevity Biotech, Inc 49
    LTT Bio-Pharma Co., Ltd. 50
    Mast Therapeutics, Inc. 51
    Mezzion Pharma Co. Ltd. 52
    miRagen Therapeutics, Inc. 53
    Nippon Shinyaku Co., Ltd. 54
    Novartis AG 55
    PharmaIN Corporation 56
    PhaseBio Pharmaceuticals, Inc. 57
    Pluristem Therapeutics Inc. 58
    Proteo, Inc. 59
    Reata Pharmaceuticals, Inc. 60
    RegeneRx Biopharmaceuticals, Inc. 61
    Sagene Pharmaceuticals, Inc. 62
    Silence Therapeutics plc 63
    Sinoxa Pharma GmbH 64
    Suda Ltd 65
    Therametrics holding AG 66
    Toray Industries, Inc. 67
    United Therapeutics Corporation 68
    Vectura Group plc 69
    Vicore Pharma AB 70
    Pulmonary Hypertension-Therapeutics Assessment 71
    Assessment by Monotherapy Products 71
    Assessment by Combination Products 72
    Assessment by Target 73
    Assessment by Mechanism of Action 77
    Assessment by Route of Administration 80
    Assessment by Molecule Type 82
    Drug Profiles 84
    (allopurinol + apocynin)-Drug Profile 84
    (chlorthalidone + valsartan)-Drug Profile 85
    ACP-009-Drug Profile 86
    ambrisentan-Drug Profile 87
    Antibody for Cancer and PAH-Drug Profile 89
    Antibody for Pulmonary Arterial Hypertension-Drug Profile 90
    APT-102-Drug Profile 91
    bardoxolone methyl-Drug Profile 93
    BAY sGCact-Drug Profile 96
    beraprost sodium nanoparticles SR-Drug Profile 97
    beraprost sodium SR-Drug Profile 98
    BIA-51058-Drug Profile 100
    BL-214-Drug Profile 101
    bosentan CR-Drug Profile 102
    C-122-Drug Profile 103
    C-21-Drug Profile 104
    C-301-Drug Profile 106
    CT-2009-Drug Profile 107
    DasKloster-1000-01-Drug Profile 108
    Drug for Pulmonary Hypertension-Drug Profile 110
    Drug for Pulmonary Hypertension-Drug Profile 111
    Elafin-Drug Profile 112
    esuberaprost sodium-Drug Profile 115
    fasudil-Drug Profile 116
    GS-4997-Drug Profile 117
    HGP-1207-Drug Profile 118
    IK-3001-Drug Profile 119
    imatinib mesylate-Drug Profile 120
    IW-1973-Drug Profile 122
    LA-419-Drug Profile 123
    lisuride-Drug Profile 124
    macitentan-Drug Profile 126
    Mydicar-Drug Profile 129
    Oligonucleotide to Inhibit Endothelin-1 for Pulmonary Arterial Hypertension-Drug Profile 131
    Oligonucleotide to Inhibit MicroRNA-145 for Pulmonary Arterial Hypertension-Drug Profile 132
    PB-1046-Drug Profile 133
    PB-1120-Drug Profile 135
    Peptide to Antagonize Urotensin-II Receptor for PAH-Drug Profile 136
    PGC-VIP-Drug Profile 137
    PK-10453-Drug Profile 138
    R-190-Drug Profile 139
    R-197-Drug Profile 141
    ralinepag-Drug Profile 142
    RGN-352-Drug Profile 143
    riociguat-Drug Profile 145
    RNAi Oligonucleotide to Inhibit miR-145 for PAH-Drug Profile 148
    selegiline + PDE-5 Inhibitor-Drug Profile 149
    selexipag-Drug Profile 150
    Small Molecule for Pulmonary Arterial Hypertension-Drug Profile 152
    Small Molecule to Antagonize Notch Receptor for Pulmonary Arterial Hypertension and Hypoxia-Drug Profile 153
    Small Molecule to Inhibit Arginase for Vascular Dysfunction, PAH and Erectile Dysfunction-Drug Profile 154
    Small Molecule to Inhibit Myosin for COPD, Asthma And Pulmonary Arterial Hypertension-Drug Profile 156
    Small Molecule to Inhibit Soluble Epoxide Hydrolase for Pulmonary Arterial Hypertension-Drug Profile 157
    Small Molecules to Activate ACE2 for Pulmonary Arterial Hypertension-Drug Profile 158
    Small Molecules to Antagonize 5-HT1B for Pulmonary Arterial Hypertension-Drug Profile 159
    Small Molecules to Inhibit MetAP-II for Oncology, Immunology, Infectious Disease, Cardiovascular and Metabolic Disorders-Drug Profile 160
    sodium nitrite-Drug Profile 161
    Stem Cell Therapy for Cardiovascular Diseases-Drug Profile 163
    SUD-004-Drug Profile 165
    Synthetic Peptide to Agonize VPAC2 for Pulmonary Arterial Hypertension-Drug Profile 166
    Synthetic Peptide to Inhibit NADPH Oxidase for Pulmonary Hypertension-Drug Profile 167
    tadalafil-Drug Profile 168
    treprostinil diolamine-Drug Profile 170
    TXA-127-Drug Profile 171
    udenafil-Drug Profile 173
    VR-876-Drug Profile 175
    Pulmonary Hypertension-Recent Pipeline Updates 176
    Pulmonary Hypertension-Dormant Projects 207
    Pulmonary Hypertension-Discontinued Products 210
    Pulmonary Hypertension-Product Development Milestones 211
    Featured News & Press Releases 211
    Appendix 220
    Methodology 220
    Coverage 220
    Secondary Research 220
    Primary Research 220
    Expert Panel Validation 220
    Contact Us 220
    Disclaimer 221

    List of Tables
    Number of Products under Development for Pulmonary Hypertension, H1 2015 15
    Number of Products under Development for Pulmonary Hypertension-Comparative Analysis, H1 2015 16
    Number of Products under Development by Companies, H1 2015 18
    Number of Products under Development by Companies, H1 2015 (Contd..1) 19
    Number of Products under Development by Companies, H1 2015 (Contd..2) 20
    Number of Products under Development by Companies, H1 2015 (Contd..3) 21
    Number of Products under Investigation by Universities/Institutes, H1 2015 22
    Comparative Analysis by Late Stage Development, H1 2015 23
    Comparative Analysis by Clinical Stage Development, H1 2015 24
    Comparative Analysis by Early Stage Development, H1 2015 25
    Products under Development by Companies, H1 2015 26
    Products under Development by Companies, H1 2015 (Contd..1) 27
    Products under Development by Companies, H1 2015 (Contd..2) 28
    Products under Development by Companies, H1 2015 (Contd..3) 29
    Products under Development by Companies, H1 2015 (Contd..4) 30
    Products under Investigation by Universities/Institutes, H1 2015 31
    Pulmonary Hypertension-Pipeline by Actelion Ltd, H1 2015 32
    Pulmonary Hypertension-Pipeline by APT Therapeutics, Inc., H1 2015 33
    Pulmonary Hypertension-Pipeline by Arena Pharmaceuticals, Inc., H1 2015 34
    Pulmonary Hypertension-Pipeline by Asahi Kasei Pharma Corp., H1 2015 35
    Pulmonary Hypertension-Pipeline by Ascendis Pharma A/S, H1 2015 36
    Pulmonary Hypertension-Pipeline by Bayer AG, H1 2015 37
    Pulmonary Hypertension-Pipeline by Bial-Portela & Ca, S.A., H1 2015 38
    Pulmonary Hypertension-Pipeline by Biolab Sanus Farmaceutica Ltda., H1 2015 39
    Pulmonary Hypertension-Pipeline by Cardioxyl Pharmaceuticals, Inc., H1 2015 40
    Pulmonary Hypertension-Pipeline by Carolus Therapeutics, Inc., H1 2015 41
    Pulmonary Hypertension-Pipeline by Celladon Corporation, H1 2015 42
    Pulmonary Hypertension-Pipeline by Celsion Corporation, H1 2015 43
    Pulmonary Hypertension-Pipeline by Corridor Pharmaceuticals Inc., H1 2015 44
    Pulmonary Hypertension-Pipeline by Cytokinetics, Inc., H1 2015 45
    Pulmonary Hypertension-Pipeline by Eli Lilly and Company, H1 2015 46
    Pulmonary Hypertension-Pipeline by Gilead Sciences, Inc., H1 2015 47
    Pulmonary Hypertension-Pipeline by HanAll Biopharma Co., Ltd., H1 2015 48
    Pulmonary Hypertension-Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2015 49
    Pulmonary Hypertension-Pipeline by Ikaria Inc., H1 2015 50
    Pulmonary Hypertension-Pipeline by Insmed Incorporated, H1 2015 51
    Pulmonary Hypertension-Pipeline by Ironwood Pharmaceuticals, Inc., H1 2015 52
    Pulmonary Hypertension-Pipeline by Lacer, S.A., H1 2015 53
    Pulmonary Hypertension-Pipeline by Longevity Biotech, Inc, H1 2015 54
    Pulmonary Hypertension-Pipeline by LTT Bio-Pharma Co., Ltd., H1 2015 55
    Pulmonary Hypertension-Pipeline by Mast Therapeutics, Inc., H1 2015 56
    Pulmonary Hypertension-Pipeline by Mezzion Pharma Co. Ltd., H1 2015 57
    Pulmonary Hypertension-Pipeline by miRagen Therapeutics, Inc., H1 2015 58
    Pulmonary Hypertension-Pipeline by Nippon Shinyaku Co., Ltd., H1 2015 59
    Pulmonary Hypertension-Pipeline by Novartis AG, H1 2015 60
    Pulmonary Hypertension-Pipeline by PharmaIN Corporation, H1 2015 61
    Pulmonary Hypertension-Pipeline by PhaseBio Pharmaceuticals, Inc., H1 2015 62
    Pulmonary Hypertension-Pipeline by Pluristem Therapeutics Inc., H1 2015 63
    Pulmonary Hypertension-Pipeline by Proteo, Inc., H1 2015 64
    Pulmonary Hypertension-Pipeline by Reata Pharmaceuticals, Inc., H1 2015 65
    Pulmonary Hypertension-Pipeline by RegeneRx Biopharmaceuticals, Inc., H1 2015 66
    Pulmonary Hypertension-Pipeline by Sagene Pharmaceuticals, Inc., H1 2015 67
    Pulmonary Hypertension-Pipeline by Silence Therapeutics plc, H1 2015 68
    Pulmonary Hypertension-Pipeline by Sinoxa Pharma GmbH, H1 2015 69
    Pulmonary Hypertension-Pipeline by Suda Ltd, H1 2015 70
    Pulmonary Hypertension-Pipeline by Therametrics holding AG, H1 2015 71
    Pulmonary Hypertension-Pipeline by Toray Industries, Inc., H1 2015 72
    Pulmonary Hypertension-Pipeline by United Therapeutics Corporation, H1 2015 73
    Pulmonary Hypertension-Pipeline by Vectura Group plc, H1 2015 74
    Pulmonary Hypertension-Pipeline by Vicore Pharma AB, H1 2015 75
    Assessment by Monotherapy Products, H1 2015 76
    Assessment by Combination Products, H1 2015 77
    Number of Products by Stage and Target, H1 2015 79
    Number of Products by Stage and Mechanism of Action, H1 2015 83
    Number of Products by Stage and Route of Administration, H1 2015 86
    Number of Products by Stage and Molecule Type, H1 2015 88
    Pulmonary Hypertension Therapeutics-Recent Pipeline Updates, H1 2015 181
    Pulmonary Hypertension-Dormant Projects, H1 2015 212
    Pulmonary Hypertension-Dormant Projects (Contd..1), H1 2015 213
    Pulmonary Hypertension-Dormant Projects (Contd..2), H1 2015 214
    Pulmonary Hypertension-Discontinued Products, H1 2015 215

    List of Figures
    Number of Products under Development for Pulmonary Hypertension, H1 2015 15
    Number of Products under Development for Pulmonary Hypertension-Comparative Analysis, H1 2015 16
    Number of Products under Development by Companies, H1 2015 17
    Number of Products under Investigation by Universities/Institutes, H1 2015 22
    Comparative Analysis by Late Stage Development, H1 2015 23
    Comparative Analysis by Clinical Stage Development, H1 2015 24
    Comparative Analysis by Early Stage Products, H1 2015 25
    Assessment by Monotherapy Products, H1 2015 76
    Assessment by Combination Products, H1 2015 77
    Number of Products by Top 10 Targets, H1 2015 78
    Number of Products by Stage and Top 10 Targets, H1 2015 78
    Number of Products by Top 10 Mechanism of Actions, H1 2015 82
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 82
    Number of Products by Top 10 Routes of Administration, H1 2015 85
    Number of Products by Stage and Top 10 Routes of Administration, H1 2015 85
    Number of Products by Top 10 Molecule Types, H1 2015 87
    Number of Products by Stage and Top 10 Molecule Types, H1 2015 87
    Actelion Ltd
    APT Therapeutics, Inc.
    Arena Pharmaceuticals, Inc.
    Asahi Kasei Pharma Corp.
    Ascendis Pharma A/S
    Bayer AG
    Bial-Portela & Ca, S.A.
    Biolab Sanus Farmaceutica Ltda.
    Cardioxyl Pharmaceuticals, Inc.
    Carolus Therapeutics, Inc.
    Celladon Corporation
    Celsion Corporation
    Corridor Pharmaceuticals Inc.
    Cytokinetics, Inc.
    Eli Lilly and Company
    Gilead Sciences, Inc.
    HanAll Biopharma Co., Ltd.
    Hanmi Pharmaceuticals, Co. Ltd.
    Ikaria Inc.
    Insmed Incorporated
    Ironwood Pharmaceuticals, Inc.
    Lacer, S.A.
    Longevity Biotech, Inc
    LTT Bio-Pharma Co., Ltd.
    Mast Therapeutics, Inc.
    Mezzion Pharma Co. Ltd.
    miRagen Therapeutics, Inc.
    Nippon Shinyaku Co., Ltd.
    Novartis AG
    PharmaIN Corporation
    PhaseBio Pharmaceuticals, Inc.
    Pluristem Therapeutics Inc.
    Proteo, Inc.
    Reata Pharmaceuticals, Inc.
    RegeneRx Biopharmaceuticals, Inc.
    Sagene Pharmaceuticals, Inc.
    Silence Therapeutics plc
    Sinoxa Pharma GmbH
    Suda Ltd
    Therametrics holding AG
    Toray Industries, Inc.
    United Therapeutics Corporation
    Vectura Group plc
    Vicore Pharma AB

    Request for Sample

    Report Url https://www.reportsweb.com//pulmonary-hypertension-pipeline-review-h1-2015&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//pulmonary-hypertension-pipeline-review-h1-2015&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//pulmonary-hypertension-pipeline-review-h1-2015&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments